Scientists warn against excessive hype around medicines that have not yet been tested.
The US food and drug administration has approved the limited use in emergency cases of two anti-malaria drugs for the treatment of patients with coronavirus. Earlier, President Donald Trump said that these medications will help turn the tide against the epidemic.
A Sunday statement from the Department of health and human services cited recent donations to the state’s drug reserve, including funds such as chloroquine and hydroxychloroquine being tested as possible medications for the treatment of COVID-19.
The statement said the office allowed ” doctors to prescribe them to hospitalized adolescents and adults with COVID-19, depending on circumstances when a clinical trial is unavailable or unacceptable.”
Last week, Trump said that these two medications may turn out to be “a gift from God,” although scientists warn of the danger of excessive hype around untested drugs.
Many researchers, including the leading US experts on infectious diseases, Anthony Fauci, have urged the public to remain cautious until larger clinical trials confirm small studies.
Two American medical organizations, the National Institutes of Health and the Office of advanced biomedical research and development are currently planning such trials.
Some in the scientific community fear that trump’s positive assessment of these drugs could lead to a shortage of them for patients who need them to treat lupus and rheumatoid arthritis – diseases for which they are approved.
According to Johns Hopkins University, more than 140,000 cases of coronavirus and 2,489 deaths have been reported in the United States.